{"id":"NCT00918879","sponsor":"AstraZeneca","briefTitle":"Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control","officialTitle":"A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb Study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2009-06-11","resultsPosted":"2011-09-26","lastUpdate":"2011-09-26"},"enrollment":213,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and exercise.","primaryOutcome":{"measure":"Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","timeFrame":"Baseline , Week 24","effectByArm":[{"arm":"Saxagliptin 5 mg","deltaMin":8.33,"sd":0.08},{"arm":"Placebo","deltaMin":8.33,"sd":0.072}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0011"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":9,"countries":["India"]},"refs":{"pmids":["27402391"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Urinary Tract Infection"]}}